title: [Key points of nursing HbeAg negative cirrhotic patients with nucleot (s) ide analogues antiviral therapy].
abstract: OBJECTIVE
  To explore the key points of nursing HBeAg negative cirrhotic patients with nucleot(s) ide analogues antiviral therapy.
  
  
  METHODS
  Patients enrolled into this study were divided into antiviral group (58 cases) and control group (53 cases). Patients from control group only received the supportive and symptomatic treatment and those from antiviral group received the additional nucleot (s) ide analogues treatment. All patients were observed during hospitalization and were followed up in clinic. Finally, we would make a nursing assessment.
  
  
  RESULTS
  All patients finished the 96-week treatment and follow-up, except 6 patients died. Alanine transferase normalization rate and HBV DNA decline were more remarkable in antiviral group than that in control group. HBV DNA negative( <500 copies/ml) after 96-week treatment were 88.7% in antiviral group and 32. 5% in control group respectively(Chi(2) = 31.427, P = 0.001).
  
  
  CONCLUSIONS
  Nucleot(s) ide analogues are significantly effective to inhibit HBV DNA replication in HBeAg negative cirrhotic patients and improve liver function. The key points of nursing these patients including appropriate patients' educating, benign nurse-patient relationship building, medical compliance emphasizing, and attentive complication observing and dealing.
authors.affiliation: Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. huang-lifen@Tom.com
authors.forename: Li-fen
authors.initials: LF
authors.lastname: Huang
authors.forename: Lu-biao
authors.initials: LB
authors.lastname: Chen
authors.forename: Li-hua
authors.initials: LH
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001942:Breast Feeding / Q000009:adverse effects; D004279:DNA, Viral / Q000187:drug effects; D005260:Female; D006513:Hepatitis B e Antigens / Q000276:immunology*; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy; D008875:Middle Aged; D009026:Mortality; D009705:Nucleosides / Q000627:therapeutic use / Q000633:toxicity*; D009732:Nursing Care; D014894:Weights and Measures
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D009705:Nucleosides; D019259:Lamivudine